drugset / Trial / NCT00134706
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Phase 2
Completed
30 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBristol-Myers Squibb · collabLowell General Hospital · collabMassachusetts General Hospital · collabOregon Health and Science University · collabWentworth-Douglass Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel. The investigators are also studying whether the measurement of two proteins in the blood may predict who will respond to the combination of docetaxel and carboplatin.
Timeline
- Start
- 2004-01
- Primary completion
- 2006-04
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |